Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “BRACHYTHERAPY”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

30 records · Page 2
All sourcesNASA NTRSDOE OSTI
DOE OSTI2021

Comparative Effectiveness Research in Localized Prostate Cancer: A 10-Year Follow-up Cohort Study

Long-term comparative effectiveness research on localized prostate cancer treatments is scarce, and evidence is lacking especially for brachytherapy. The aim of this study was to assess the long-term impact of the side effects of radical prostatectomy, brachytherapy, and external radiation therapy on patients with localized prostate cancer at 10 years, using propensity score analyses.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
DOE OSTI2021

Nuclear data for reactor production of 131 Ba and 133 Ba

The newest radioisotope for brachytherapy treatment of prostate cancer is 131 Cs (t 1/2 = 9.69 d, 100% EC). Generated via electron capture decay of 131 Ba (t 1/2 = 11.6 d, 100% EC), 131 Cs has been used in brachytherapy for prostate cancer since 2004. The 131 Ba parent is produced through neutron capture of enriched 130 Ba in a nuclear reactor. For large-scale production of 131 Ba, an accurate knowledge of production and burnup cross sections of 131 Ba are essential. Here, we report two group cross sections (thermal and resonance integrals) for 130 Ba and 131 Ba and a new measure of the half-life of 131 Ba. Targets consisting of milligram quantities of enriched 130Ba (~35%) were irradiated in Oak Ridge National Laboratory's High Flux Isotope Reactor at thermal and resonance neutron fluxes of (1.9–2.1) × 10 15 and (5.8–7.0) × 10 13 neutrons·cm -2 s -1 , respectively, for durations ranging from 3 to 26 days. In addition, cadmium covered samples of 130 Ba were irradiated for 1 hour at 12.6% full reactor power (10.7 MW). The yield of 131 Ba approaches a saturation value of ~60 GBq (~1.6 Ci) per mg of 130 Ba for 20 days irradiation at a thermal neutron flux of 1.8 × 10 15 n·s -1 ·cm -2 , with a thermal/epithermal ratio of ~30. Under the above experimental conditions, the two group cross sections of 130 Ba are 6.9 ± 0.5 b (thermal, σ 0 ) and 173 ± 7 b (resonance, I 0 ). These values represent the sum of cross sections to metastable and ground states of 131 Ba. For 131 Ba, the empirically measured thermal cross section is 200 ± 50 b assuming an I 0 /σ 0 of 10. This cross section is reported for the first time. Further, the half-life of 131 Ba was remeasured to be 11.657 ± 0.008 d. Lastly, this study also resulted in the co-production of 133 Ba (t 1/2 = 10.52 y, 100% EC). The experimental yield of 133 Ba is ~370 MBq (~10 mCi) per mg of 132 Ba (thin target) for one cycle irradiation in the High Flux Isotope Reactor, and measured two-group 132 Ba cross sections are 7.2 ± 0.2 b and 39.9 ± 1.3 b. These values also represent the sum of cross sections to metastable and ground states of 133 Ba.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
DOE OSTI2020

Investigation of Radiological Contamination at Parks in the Gateway National Recreation Area - 20350

In 2005, the National Park Service was notified that elevated radiation levels were detected at Great Kills Park during a baseline radiological mapping effort conducted by the Counter Terrorism Bureau of the New York City Police Department and the United States Department of Energy. Great Kills Park is in the Staten Island Unit of the Gateway National Recreation Area. A records search determined that approximately 280 acres of the park was established over an area in which the New York City Department of Sanitation placed approximately 15.1 million cubic yards of waste fill from 1944 to 1948. Since 2005, a series of response actions and investigations were conducted on behalf of the National Park Service to mitigate risk to human health and the environment and to determine the nature of radiological contamination at Great Kills Park. The findings support that radiological contamination is related to certain components of waste fill, including incinerator residue from both on and offsite incinerators, coal ash from the historical use of coal-fired boilers for heating, and incidental radiological artifacts in the waste fill due to their historical use and subsequent disposal. A majority of the radiological artifacts were determined to contain radium-226 and included radioluminescent markers, radium impregnated switch board buttons, radium paint containers, and brachytherapy devices. The National Park Service has several other Parks in the Gateway National Recreation Area that were established in areas with a similar history to Great Kills Park, and overlie waste fill historically placed during landfilling operations, including Spring Creek Park and Dead Horse Bay. Over the last year, the National Park Service has performed additional radiological investigations at Great Kills Park as part of the ongoing Remedial Investigation under the Comprehensive Environmental Response, Compensation, and Liability Act. In addition, preliminary radiological investigations were performed at Spring Creek Park and Dead Horse Bay Park in the Jamaica Bay Unit of Gateway National Recreation Area. These investigation activities identified gamma radiation levels above the ambient level, several of which were attributable to radiological artifacts similar in nature to those recovered at Great Kills Park. Ongoing investigations at Parks in the Gateway National Recreation Area support an association between radiological contamination and historical landfilling practices that were common prior to the regulation and control of radioactive materials. (authors)

12 MANAGEMENT OF RADIOACTIVE AND NON-RADIOACTIVE W↗
DOE OSTI2025

Results of a Geant4 benchmarking study for bio‐medical applications, performed with the G4‐Med system

Geant4, a Monte Carlo Simulation Toolkit extensively used in bio-medical physics, is in continuous evolution to include newest research findings to improve its accuracy and to respond to the evolving needs of a very diverse user community. In 2014, the G4-Med benchmarking system was born from the effort of the Geant4 Medical Simulation Benchmarking Group, to benchmark and monitor the evolution of Geant4 for medical physics applications. The G4-Med system was first described in our Medical Physics Special Report published in 2021. Results of the tests were reported for Geant4 10.5. Purpose In this work, we describe the evolution of the G4-Med benchmarking system. Methods The G4-Med benchmarking suite currently includes 23 tests, which benchmark Geant4 from the calculation of basic physical quantities to the simulation of more clinically relevant set-ups. New tests concern the benchmarking of Geant4-DNA physics and chemistry components for regression testing purposes, dosimetry for brachytherapy with a 125 I source, dosimetry for external x-ray and electron FLASH radiotherapy, experimental microdosimetry for proton therapy, and in vivo PET for carbon and oxygen beams. Regression testing has been performed between Geant4 10.5 and 11.1. Finally, a simple Geant4 simulation has been developed and used to compare Geant4 EM physics constructors and physics lists in terms of execution times. Results In summary, our EM tests show that the parameters of the multiple scattering in the Geant4 EM constructor G4EmStandardPhysics_option3 in Geant4 11.1, while improving the modeling of the electron backscattering in high atomic number targets, are not adequate for dosimetry for clinical x-ray and electron beams. Therefore, these parameters have been reverted back to those of Geant4 10.5 in Geant4 11.2.1. The x-ray radiotherapy test shows significant differences in the modeling of the bremsstrahlung process, especially between G4EmPenelopePhysics and the other constructors under study (G4EmLivermorePhysics, G4EmStandardPhysics_option3, and G4EmStandardPhysics_option4). These differences will be studied in an in-depth investigation within our Group. Improvement in Geant4 11.1 has been observed for the modeling of the proton and carbon ion Bragg peak with energies of clinical interest, thanks to the adoption of ICRU90 to calculate the low energy proton stopping powers in water and of the Linhard–Sorensen ion model, available in Geant4 since version 11.0. Nuclear fragmentation tests of interest for carbon ion therapy show differences between Geant4 10.5 and 11.1 in terms of fragment yields. In particular, a higher production of boron fragments is observed with Geant4 11.1, leading to a better agreement with reference data for this fragment. Conclusions Based on the overall results of our tests, we recommend to use G4EmStandardPhysics_option4 as EM constructor and QGSP_BIC_HP with G4EmStandardPhysics_option4, for hadrontherapy applications. The Geant4-DNA physics lists report differences in modeling electron interactions in water, however, the tests have a pure regression testing purpose so no recommendation can be formulated.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
DOE OSTI2021

A benchmarking study of Geant4 for Auger electrons emitted by medical radioisotopes

Auger emitting radioisotopes are of great interest in targeted radiotherapy because, once internalised in the tumour cells, they can deliver dose locally to the radiation sensitive targets, while not affecting surrounding cells. Geant4 is a Monte Carlo code widely used to characterise the physics mechanism at the basis of targeted radiotherapy. Here, we benchmarked the modelling of the emission of Auger electrons in Geant4 deriving from the decay of 123 I, 124 I, 125 I radionuclides against existing theoretical approaches. We also compared Geant4 against reference data in the case of 131 Cs, which is of interest for brachytherapy. In the case of 125 I and 131 Cs, the simulation results are compared to experimental measurements as well. Good agreement was found between Geant4 and the reference data. As far as we know, this is the first study aimed to benchmark against experimental measurements the emission of Auger electrons in Geant4 for radiotherapy applications.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗
NASA NTRS2006

Radiation-Induced Leukemia at Doses Relevant to Radiation Therapy: Modeling Mechanisms and Estimating Risks

Because many cancer patients are diagnosed earlier and live longer than in the past, second cancers induced by radiation therapy have become a clinically significant issue. An earlier biologically based model that was designed to estimate risks of high-dose radiation induced solid cancers included initiation of stem cells to a premalignant state, inactivation of stem cells at high radiation doses, and proliferation of stem cells during cellular repopulation after inactivation. This earlier model predicted the risks of solid tumors induced by radiation therapy but overestimated the corresponding leukemia risks. Methods: To extend the model to radiation-induced leukemias, we analyzed in addition to cellular initiation, inactivation, and proliferation a repopulation mechanism specific to the hematopoietic system: long-range migration through the blood stream of hematopoietic stem cells (HSCs) from distant locations. Parameters for the model were derived from HSC biologic data in the literature and from leukemia risks among atomic bomb survivors v^ ho were subjected to much lower radiation doses. Results: Proliferating HSCs that migrate from sites distant from the high-dose region include few preleukemic HSCs, thus decreasing the high-dose leukemia risk. The extended model for leukemia provides risk estimates that are consistent with epidemiologic data for leukemia risk associated with radiation therapy over a wide dose range. For example, when applied to an earlier case-control study of 110000 women undergoing radiotherapy for uterine cancer, the model predicted an excess relative risk (ERR) of 1.9 for leukemia among women who received a large inhomogeneous fractionated external beam dose to the bone marrow (mean = 14.9 Gy), consistent with the measured ERR (2.0, 95% confidence interval [CI] = 0.2 to 6.4; from 3.6 cases expected and 11 cases observed). As a corresponding example for brachytherapy, the predicted ERR of 0.80 among women who received an inhomogeneous low-dose-rate dose to the bone marrow (mean = 2.5 Gy) was consistent with the measured ERR (0.62, 95% Cl =-0.2 to 1.9). Conclusions: An extended, biologically based model for leukemia that includes HSC initiation, inactivation, proliferation, and, uniquely for leukemia, long-range HSC migration predicts, %Kith reasonable accuracy, risks for radiationinduced leukemia associated with exposure to therapeutic doses of radiation.

Shuryak, Igor↗
DOE OSTI2021

A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy: An ASTRO Consensus Document

Radiopharmaceutical therapy (RPT) is an area of projected growth and importance with several agents in clinical use, new agents in late-phase clinical trials, and many others under testing and development. This article proposes a framework for developing pathways of care that can be broadly applied to all RPTs, representing the current status of RPT. It suggests foundational elements for many pathways of care for patients with cancer and concludes with areas in active development and the future horizon for RPT treatment centers. Developing a framework for patient-centered pathways of care is a critical step in establishing RPT as standard therapy for patients with a diverse spectrum of cancers. This expected increase in RPT treatment options will affect a much larger population of patients with complex cancer. It will also require enhanced coordination and collaboration among appropriately qualified personnel with diverse expertise in image acquisition, image interpretation, quantitative imaging, dosimetry calculation, radiation quality assurance and safety as well as oncology care and RPT-induced sequelae and response assessment. The essential role of this evolving RPT care team within multidisciplinary oncology care is a cornerstone of this framework for a patient-centered pathway of care for RPT. Given the status of current RPT practice and the horizon for future applications, this patient-centered pathway of care guidance is timely and should help inform future clinical RPT practice paradigms. A task force was recruited from the Theranostic Working Group of the American Society for Radiation Oncology (ASTRO) in May 2019 with equal representation from the nuclear medicine community. The task force expanded on a framework that was originally conceived by the Working Group for patient-centered care. This framework was developed to incorporate the strengths of both radiation oncologists and nuclear medicine physicians. The manuscript was then developed by the task force and posted on the ASTRO website for a 6-week public comment period ending in July 2020. Comments were adjudicated, and the draft was sent to external organizations for potential endorsement. This document was sent to the ASTRO Board of Directors in October 2020 for approval.

62 RADIOLOGY AND NUCLEAR MEDICINE↗